ADP-mimicking Platelet Aggregation Caused by Rugosin E, an Ellagitannin Isolated from Rosa rugosa Thunb

Summary

Among the nine ellagitannins, rugosin E was the most potent platelet aggregating agent with an EC₅₀ of 1.5 ± 0.1 µM in rabbit platelets and 3.2 ±0.1 µM in human platelets. The aggregations caused by rugosin E and ADP were inhibited by EGTA, PGE1, mepacrine, sodium nitroprusside and neomycin, but not by indomethacin, verapamil, TMB-8, BN52021 and GR32191B. Rugosin E-induced thromboxane formation was suppressed by indomethacin, EGTA, PGE,, verapamil, mepacrine, TMB-8 and neomycin. ADP-scavenging agents, such as CP/CPK and apyrase inhibited concentration-dependently ADP (20 εM)-, but not rugosin E (5 εM)-induced platelet aggregation. In thrombin (0.1 U/ml)-treated and degranulated platelets, rugosin E and ADP still caused 63.5 ± 3.0% and 61.2 ± 3.5% of platelet aggregation, respectively. Selective ADP receptor antagonists, ATP and FSBA inhibited rugosin E- and ADP-induced platelet aggregations in a concentration-dependent manner. Both rugosin E and ADP did not induce platelet aggregation in ADP (1 mM)-desensitized platelets. In contrast to ADP, rugosin E did not decrease cAMP formation in washed rabbit platelets. Both rugosin E and ADP did not cause phosphoinositide breakdown in [³H]myo-inositol-labeled rabbit platelets. In fura-2/AM- load platelets, both rugosin E and ADP induced increase in intracellular calcium concentration and these responses were inhibited by ATP and PGEj. All these data suggest that rugosin E may be an ADP receptor agonist in rabbit platelets.

• References

• 1 Teng CM, Ko FN, Yu SM. Inventory of exogenous factors affecting platelet aggregation isolated from plant sources. Thromb Haemost 1994; 71: 0517-0520
• 2 Ross R. The pathogenesis of atherosclerosis – An update. N Engl J Med 1986; 314: 0488-0500
• 3 Hirsh J. Hyperreactive platelets and complications of coronary artery disease. N Engl J Med 1987; 316: 1543-1544
• 4 Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance. J Am Coll Cardio 1990; 16: 0207-0222
• 5 Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177-1209
• 6 Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J 1986; 233: 0309-0319
• 7 McClure MO, Kakkar A, Cusack NJ, Bom GVR. Evidence for the dependence of arterial haemostasis on ADP. Proc R Soc London Ser B 1988; 234: 0255-0262
• 8 Kim BK, Zamecnik P, Taylor G, Guo MJ, Blackburn GM. Antithrombotic effect of ß,ß’-monochloromethylene diadenosine 5',5”’-Pl, P4-tetraphos- phate. Proc Natl Acad Sci USA 1992; 89: 11056-11058
• 9 Hatano T, Ogawa N, Shingu T, Okuda T. Rugosins D, E, F and G dimeric and trimeric hydrolyzable tannins with valoneoyl group(s), from flower petals of Rosa rugosa Thunb. Chem Pharm Bull 1990; 38: 3341-3346
• 10 Oukda T, Hatano T, Yazaki K, Ogawa N. Rugosin A, B, C and Praecoxin A tannins having a valoneoyl group. Chem Pharm Bull 1982; 30: 4230-4233
• 11 Yoshida T, Maruyama Y, Memon MU, Shingu T, Okuda T. Gemins D, E and F ellagitannins from Geum japonicum. Phytochemistry 1985; 24: 1041-1046
• 12 Okuda T, Yoshida T, Ashida M, Yazaki K. Tannins of casuarina and stachyurus species. Part 1. Structures of pendunculagin, casuarictin, strictinin casurarinin, casuariin, and stachyurin J Chem Soc Perkin Trans 1983; 1: 1765-1772
• 13 Nonaka G, Ishimaru K, Azuma R, Ishimatsu M, Nishioka I. Tannins and related compounds. LXXXV. Structures of novel C-glycosidic ellagitannins, grandinin and pterocarinins A and B. Chem Pharm Bull 1989; 37: 2071-2077
• 14 Nonaka G, Sakai T, Tanaka T, Mihashi K, Nishioka I. Tannins and related compounds. XCVII. Structure revision of C-glycosidic ellagitannins, cas- talagin, vescalagin, casuarinin and stachyurin, and related hydrolyzable tannins. Chem Pharm Bull 1990; 38: 2151-2156
• 15 Nonaka G, Harada M, Nishioka I. Eugeniin, a new ellagitannin from cloves. Chem Pharm Bull 1980; 28: 0685-0687
• 16 Okuda T, Yoshida T, Hatano T, Yazaki K, Ashida M. Ellagitannins of casuarinaceae, stachyuraceae and myrtaceae. Phytochemistry 1982; 21: 2871-2874
• 17 Teng CM, Chen WY, Ko WC, Ouyang C. Antiplatelet effect of butylide-nephthalide. Biochim Biophys Acta 1987; 924: 0375-0382
• 18 O’Brien JR. Platelet aggregation. Part II. Some results from a new method of study. J Clin Pathol 1962; 15: 0452-0455
• 19 De Luca M, McElroy WD. Purification and properties of firefly luciferase. Methods Enzymol 1978; 57: 0003-0015
• 20 Reimers HJ, Kinlough-Rathbone RL, Cazenave JP, Senyi AF, Hirsh J, Packham MA, Mustard JF. In vitro and in vivo functions of thrombin-treated platelet. Thromb Haemost 1976; 35: 0151-0166
• 21 Huang EM, Detwiler TC. The effect of lithium on platelet phosphoinositide metabolism. Biochem J 1986; 236: 0895-0901
• 22 Neylon CB, Summers RJ. Stimulation of αj-adrenoceptors in rat kidney mediates increased inositol phospholipid hydrolysis. Br J Pharmacol 1987; 0367-0376
• 23 Pollock WK, Rink TJ. Thrombin and ionomycin can raise platelet cytosolic Ca²⁺to micromolar levels by discharge of internal Ca²⁺stores: Studies using fura-2. Biochem Biophys Res Commun 1986; 139: 0308-0314
• 24 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
• 25 Lips PM, Sixma JJ, Schiphorst ME. Binding of adenosine diphosphate to human blood platelets and to isolated blood platelet membranes. Biochim Biophys Acta 1980; 628: 0451-0467
• 26 Colman RW. Platelet activation: role of an ADP receptor. Seminars in Hematology 1986; 23: 0119-0128
• 27 Colman RW. Aggregin: a platelet ADP receptor that mediates activation. FASEB J 1990; 4: 1425-1435
• 28 Majerus PW, Wilson DB, Connolly TM, Bross TE, Neufeld EJ. Phospho-inositide turnover provides a link in stimulus-response coupling. Trends Biochem Sci 1985; 10: 0168-0170
• 29 Detwiler TC, Charo IF, Feinman RD. Evidence that calcium regulates platelet function. Thromb Haemost 1978; 40: 0207-0211
• 30 Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A₂and prostacyclin. Pharmacol Rev 1978; 30: 0293-0331
• 31 White JG, Gerrard JM. Platelets: a multidisciplinary approach. Raven Press; New York: 1978
• 32 Shen TY, Hwang SB, Chang MN, Doebber TW, Lam MHT, Wu MS, Wang X, Han GQ, Li RZ. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper fatokadsura): specific inhibition of in vitro and in vivo platelet-activating factor induced effects. Proc Natl Acad Sci USA 1985; 82: 0672-0676
• 33 Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science 1984; 225: 1365-1370
• 34 Feinstein MB, Egan JJ, Sha’nfi RI, White J. The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD₂, PGE₁foskolin). Biochem Biophys Res Commun 1983; 13: 0598-0604
• 35 Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987; 39: 0163-0196
• 36 Hoffmann SL, Prescott SM, Majerus PW. The effects of mepacrine and p-bromophenacyl bromide on arachidonic acid release in human platelets. Arch Biochem Biophys 1982; 215: 0237-0244
• 37 Gabev E, Kasianowicz J, Abbott T, McLaughlin S. Binding of neomycin to phosphatidyl 4,5-bisphosphate (PIP₂). Biochim Biophys Acta 1989; 979: 0105-0112
• 38 Lips PM, Sixma JJ, Schiphorst ME. Binding of adenosine diphosphate to human blood platelets and to isolated blood platelet membranes. Biochim Biophys Acta 1980; 628: 0451-0467
• 39 MacIntyre DE, Pollock WK, Shaw AM, Bushfield M, MacMillan LJ, McNicol A. Agonist-induced inositol phospholipid metabolism and Ca²⁺flux in human platelet activation. Adv Exp Biol Med 1985; 192: 0127-0144
• 40 Vickers JD, Kinlough-Rathbone RL, Packham MA, Mustard JF. Inositol phospholipid metabolism in human platelets stimulated by ADP. Eur J Biochem 1990; 193: 0521-0528
• 41 Packham MA, Livne AA, Ruben DH, Rand ML. Activation of phospholipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: effect of diacylglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid. Biochem J 1993; 290: 0849-0856
• 42 Raha S, Jones GD, Gear ARL. Sub-second oscillation of inositol 1,4,5- trisphosphate and inositol 1,3,4,5-tetrakisphosphate during platelet activation by ADP and thrombin: lack of correlation with calcium kinetics. Biochem J 1993; 292: 0849-0856
• 43 Hallam TJ, Rink TJ. Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator quin 2. J Physiol (Lond.) 1985; 368: 0131-0146
• 44 Mills DCB, Figures WR, Scearce LM, Stewart GJ, Colman RF, Colman RW. Two mechanisms for inhibition of ADP-induced platelet shape change by 5’-fluorosulforyl-benzoyladenosine. J Biol Chem 1985; 260: 8078-8083
• 45 Macfarlane DE, Srivastava PC, Mills DCB. 2-Methylthioadenosine [ß-³²P]diphosphate. Antagonist and radioligand for the receptor that inhibits the accumulation of cAMP in intact blood platelets. J Clin Invest 1983; 71: 0420-0425
• 46 Macfarlane DE, Mills DCB, Srivastava PC. Binding of 2-azidoadenosine [ß-³²P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 1982; 21: 0544-0549
• 47 Huang TF, Wang WJ, Teng CM, Ouyang C. Mechanism of action of the antiplatelet peptide, arietin, from Bitis arietans venom. Biochim Biophys Acta 1991; 1074: 0144-0150